medigraphic.com
ISSN 1817-5996 (Digital)

2020, Número 3

<< Anterior Siguiente >>

Rev Cub de Reu 2020; 22 (3)


Actividad y tratamiento de la artritis reumatoide

Urbina ACY, Carrera MGY, Quintana DOS, Guama BLN

Idioma: Español
Referencias bibliográficas: 27
Paginas: 1-14
Archivo PDF: 424.56 Kb.


RESUMEN

El diagnóstico y el tratamiento de la artritis reumatoide temprana en el curso de la enfermedad proporcionan alivio de los síntomas y también previene el daño estructural a largo plazo y el deterioro funcional, con una mejora concomitante en la calidad de vida. El propósito de este estudio es exponer algunos enfoques de la artritis reumatoide en cuanto al tratamiento y comportamiento de la actividad de la enfermedad. El reconocimiento de los pacientes de que su enfermedad progresa rápidamente es fundamental para identificar candidatos en los cuales la terapia intensiva puede tener el mayor impacto, en términos de prevenir la progresión de la enfermedad. Los datos acumulados muestran que las estrategias de tratamiento intensivo con agentes biológicos, especialmente los inhibidores del factor de necrosis tumoral, son más eficaces que la monoterapia secuencial o la terapia de combinación progresiva. Estos muestran una eficacia sustancial en combinación con el metotrexato, ya que proporcionan beneficios y mejoras rápidas y sustanciales a los pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Emery P, Seto Y. Role of biologics in early arthritis. Exp Rheumatol. 2003 [Acceso 05/03/2020];21(Suppl 30):S191-S194. Disponible en: https://www.clinexprheumatol.org/article.asp?a=2214

  2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum. 2002 [Acceso 05/01/2020];46:328-46. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.10148

  3. Chen S, Gill MA, Luu CH, Takami S. Pain and rheumatoid arthritis: an update. Drug Topics. 2000 Apr;3:47-56.

  4. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, van der Heijde DMFM, Huizinga TWJ, Kerstens PJMS, et al. Clinical outcomes of four different treatment strategies in patients with recent-onset rheumatoid arthritis: 5-year results of the Best Study. Ann Rheum Dis. 2008;67(Suppl II):187.

  5. Arvidsson NG, Gubjornsson B, Hallgren R, Larrson A. Concordant message of different inflammatory markers in patients with rheumatoid arthritis. Ups J Med Sci. 1998 [Acceso 22/07/2020];103:35-42. Disponible en: https://www.tandfonline.com/doi/pdf/10.3109/03009739809178943

  6. Skogh T, Gustafsson D, Kjellberg M, Husberg M. Twenty-eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis. 2003 [Acceso 05/03/2020];62:681-2. Disponible en: https://ard.bmj.com/content/annrheumdis/62/7/681.full.pdf

  7. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008 [Acceso 22/07/2020];67:1360-4. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.24123

  8. Salaffi F, Cimmino MA, Leardini G, Gasparini S, Grassi W, Epidemiology Study Group of the Italian Society of Rheumatology. Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the disease activity score including 28 joints compared with the clinical disease activity index. Clin Exp Rheumatol. 2009 [Acceso 22/07/2020];27:552-9. Disponible en: https://www.clinexprheumatol.org/article.asp?a=3665

  9. Balsa A, de Miguel E, Castillo C, Peiteado D, Martín-Mola E. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology. 2010 [Acceso 28/07/2020];49:683-90. Disponible en: https://academic.oup.com/rheumatology/article/49/4/683/1790047

  10. Garnero P, Geusens P, Landewé R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S54-S58.

  11. Emery P. The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis. The value of HLA genotyping and the oncological analogy. J Rheumatol. 1997;24:1436-42.

  12. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008 [Acceso 05/08/2020];47:392-8. Disponible en: https://academic.oup.com/rheumatology/article-pdf/47/4/392/5060038/kem257.pdf

  13. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002 [Acceso 22/07/2020];46:357-365. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.10117

  14. Mitka M. Early rheumatoid arthritis treatments weighed. JAMA. 2005;294:3073-4.

  15. McInnes IB. Attitudes of rheumatologists to rapidly progressing rheumatoid arthritis [abstract]. Rheumatology. 2007 [Acceso 03/08/2020];6(Suppl 1):i89. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/202095

  16. Sesin CA, Bingham CO. 3rd Remission in rheumatoid arthritis: Wishful thinking or clinical reality? Semin Arthritis Rheum. 2005;35:185-196.

  17. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.

  18. Hen S, Gill MA, Luu CH, Takami S. Pain and rheumatoid arthritis: An update. Drug Topics. 2000 April;3:47-56.

  19. Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol. 1999 [Acceso 05/03/2020];26(Suppl 57):22-8. Disponible en: https://europepmc.org/article/med/10328139

  20. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet. 2004 [Acceso 14/08/2020];364:263-9. Disponible en: http://www.angelfire.com/ar3/reumatologia0/jruiz.pdf

  21. Odeh M. New insights into the pathogenesis and treatment of rheumatoid arthritis. Clin Immunol Immunopathol. 1997 [Acceso 22/07/2020];83:103-16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9143371/

  22. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al, American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.

  23. American College of Rheumatology, Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996;39:713-22.

  24. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet. 2008 [Acceso 29/07/2020];372:375-82. Disponible en: https://www.academia.edu/download/55013587/s0140-6736_2808_2961000-420171115-2210-1tk88eq.pdf

  25. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 [Acceso 07/08/2020];54:26-37. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.21519

  26. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelvemonth randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 [Acceso 22/07/2020];52:27-35. Disponible en: https://scholar.google.com.cu/scholar?output=instlink&q=info:cOnhyDVKC3wJ:scholar.google.com/&hl=es&as_sdt=0,5&scillfp=3821783310412170914&oi=lle

  27. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Research & Therapy. 2011 [Acceso 06/08/2020];13(Suppl 1):S3. Disponible en: https://arthritis-research.biomedcentral.com/articles/10.1186/1478-6354-13-S1-S3




2020     |     www.medigraphic.com